Post-surgery osimertinib delays disease recurrence in patients with localised non-small-cell lung cancer
'The improvement in disease-free survival seen in this study strongly supports the use of this targeted therapy in earlier stage disease, which has a significant risk of recurrence despite surgical treatment and chemotherapy,' said ASCO CMO and Executive Vice President Richard Schilsky.
Treatment with targeted therapy osimertinib (Tagrisso) following surgery for localised non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation significantly improved disease-free survival in a phase III study.
Of patients with stage II-IIIA NSCLC who received osimertinib, 90% were alive at two years without the cancer recurring, compared with 44% who received a placebo.
In stage II-IIIA patients, the risk of disease recurrence or death was reduced by 83% for patients treated with adjuvant osimertinib after surgery compared to placebo.
The findings come from an unplanned interim analysis presented as part of the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
Study at a Glance
|
Focus |
Adjuvant osimertinib in patients with localised NSCLC with EGFR mutation |
|
Population |
682 patients with primary non-squamous stage IB/II/IIIA NSCLC and EGFR mutation |
|
Findings |
83% reduction in the risk of disease recurrence or death in patients with stage II-IIIA disease |
|
Significance |
Establishes osimertinib as alternative front-line therapy for localised NSCLC with EGFR mutation |
To view full article and watch the video summary,
register to OnMedica and then click
'View full content'.
